Inno-Gene Past Earnings Performance
Past criteria checks 0/6
Inno-Gene's earnings have been declining at an average annual rate of -24.3%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 3.9% per year.
Key information
-24.3%
Earnings growth rate
-24.3%
EPS growth rate
| Life Sciences Industry Growth | 26.0% |
| Revenue growth rate | -3.9% |
| Return on equity | -21.4% |
| Net Margin | -288.0% |
| Next Earnings Update | 12 Jul 2024 |
Recent past performance updates
Recent updates
Here's Why We Think Inno-Gene (WSE:IGN) Might Deserve Your Attention Today
Jul 25
Here's Why We Think Inno-Gene (WSE:IGN) Is Well Worth Watching
Apr 05Here's Why I Think Inno-Gene (WSE:IGN) Is An Interesting Stock
Dec 28Should You Be Adding Inno-Gene (WSE:IGN) To Your Watchlist Today?
Aug 28We Wouldn't Rely On Inno-Gene's (WSE:IGN) Statutory Earnings As A Guide
Feb 17
Revenue & Expenses Breakdown
How Inno-Gene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -1 | 2 | 0 |
| 31 Dec 23 | 1 | -1 | 2 | 0 |
| 30 Sep 23 | -14 | -4 | -6 | 0 |
| 30 Jun 23 | -13 | -5 | -5 | 0 |
| 31 Mar 23 | -9 | -6 | -1 | 0 |
| 31 Dec 22 | 0 | -2 | 1 | 0 |
| 30 Sep 22 | 24 | 0 | 15 | 0 |
| 30 Jun 22 | 33 | 3 | 16 | 0 |
| 31 Mar 22 | 39 | 10 | 15 | 0 |
| 31 Dec 21 | 30 | 6 | 12 | 0 |
| 30 Sep 21 | 23 | 6 | 8 | 0 |
| 30 Jun 21 | 15 | 5 | 4 | 0 |
| 31 Mar 21 | 6 | 1 | 2 | 0 |
| 31 Dec 20 | 5 | 0 | 1 | 0 |
| 30 Sep 20 | 3 | 1 | 1 | 0 |
| 30 Jun 20 | 2 | 0 | 1 | 0 |
| 31 Mar 20 | 1 | 0 | 1 | 0 |
| 31 Dec 19 | 1 | 0 | 1 | 0 |
| 30 Sep 19 | 1 | -1 | 1 | 0 |
| 30 Jun 19 | 2 | 1 | 1 | 0 |
| 31 Mar 19 | 3 | 1 | 1 | 0 |
| 31 Dec 18 | 3 | 0 | 2 | 0 |
| 30 Sep 18 | 3 | 1 | 2 | 0 |
| 30 Jun 18 | 3 | 1 | 2 | 0 |
| 31 Mar 18 | 3 | 1 | 2 | 0 |
| 31 Dec 17 | 3 | 1 | 2 | 0 |
| 30 Sep 17 | 4 | 0 | 3 | 0 |
| 30 Jun 17 | 4 | -1 | 3 | 0 |
| 31 Mar 17 | 4 | -2 | 3 | 0 |
| 31 Dec 16 | 5 | -3 | 4 | 0 |
| 30 Sep 16 | 5 | -3 | 5 | 0 |
| 30 Jun 16 | 4 | -3 | 4 | 0 |
| 31 Mar 16 | 5 | -1 | 4 | 0 |
| 31 Dec 15 | 4 | -1 | 4 | 0 |
| 30 Sep 15 | 4 | 1 | 3 | 0 |
| 30 Jun 15 | 4 | 2 | 3 | 0 |
| 31 Mar 15 | 4 | 2 | 2 | 0 |
| 31 Dec 14 | 4 | 2 | 2 | 0 |
| 30 Sep 14 | 4 | 0 | 2 | 0 |
| 30 Jun 14 | 4 | -1 | 2 | 0 |
| 31 Mar 14 | 3 | -1 | 2 | 0 |
| 31 Dec 13 | 3 | 0 | 2 | 0 |
| 30 Sep 13 | 3 | 0 | 2 | 0 |
Quality Earnings: IGN is currently unprofitable.
Growing Profit Margin: IGN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IGN is unprofitable, and losses have increased over the past 5 years at a rate of 24.3% per year.
Accelerating Growth: Unable to compare IGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IGN is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-1.7%).
Return on Equity
High ROE: IGN has a negative Return on Equity (-21.39%), as it is currently unprofitable.